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ports indicate an increasing incidence.5 This 
aggressive disease is often sporadic but may 
occur as part of a genetic syndrome.6 cetani 
et al. present a clinical and genetic update on 
parathyroid carcinoma in this issue.7
albright et al. not only described primary 
hyperparathyroidism in 1932,8 but also pseu-
dohyperparathyroidism,9 i.e. resistance to the 
action of parathyroid hormone, and pseudo-
psuedohypoparathyroidism,10 the two latter 
nowadays classified as disorders of PTH/PTHrP 
signaling.11 in the present issue, cianferotti and 
Brandi give an overview of the molecular bi-
ology of PTH/PTHrP signaling, as well as the 
related phenotypes and diagnostic work-up in 
disorders of PTH/PTHrP signaling.12
lastly, in this issue of Minerva Endocrino-
logica, Maffezzoni and Formenti review the 
physiology of bone metabolism and turnover 
and give an overview on acromegaly and bone.13 
in acromegaly, characterized by excess secre-
tion of GH and IGF-1, both decreased fracture 
risk 14 as well as increased vertebral fracture 
risk despite normal bone mineral density 15 has 
been reported. Bone metabolism in acromegaly 
has been a matter of debate in the last decades.
The authors of the current articles are ac-
knowledged experts in their fields. I believe 
that the readers of Minerva Endocrinologica 
will value and appreciate this update on the 
disorders of calcium, phosphate and bone.
This issue of Minerva Endocrinologica pro-vides an update on disorders of calcium, 
phosphate and bone. Primary hyperparathy-
roidism is the most common cause of hypercal-
cemia and the third most common endocrine 
disease after diabetes and hyperthyroidism.1 
increased incidences are reported along the 
introduction of routine calcium screening, es-
pecially in the Western countries. This is paral-
leled by a shift from symptomatic disease, in-
volving the kidneys, skeleton, digestive tract, 
neurocognition and cardiovascular system, to 
subtle or non-specific symptoms. Surgery is 
not indicated in all cases, but imaging is rec-
ommended before surgery in all patients and 
mandatory before re-operation.2, 3 99mTc-ses-
tamibi scintigraphy is still first-line imaging, 
while the role of novel PET tracers such as 11c-
methione and 18F-fluorocholine in parathyroid 
imaging is being explored.2, 3 in this issue, 
Treglia et al. give an overview on the diag-
nostic performance of different imaging meth-
ods in primary hyperparathyroidism.4 While 
primary hyperparathyroidism almost always 
is due to benign disorders of the parathyroid 
glands (single or double adenomas in ~80% of 
cases and hyperplasia in ~15-20%), parathy-
roid carcinoma - especially in patients suffer-
ing from severe, symptomatic PTH-dependent 
hypercalcemia must not be overlooked.1, 5 
Parathyroid carcinoma is rare (<1%) but re-
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